#heateor_sss_mastodon_popup_bg,#heateor_sss_popup_bg{--wpr-bg-9b170f74-f044-495f-b4b6-265a96f3b718: url('https://www.delveinsight.com/blog/blog/wp-content/plugins/sassy-social-share/images/transparent_bg.png');}.rll-youtube-player .play{--wpr-bg-931a7eaf-da5c-442e-b74e-7d3a8ebda895: url('https://www.delveinsight.com/blog/wp-content/plugins/wp-rocket/assets/img/youtube.png');}

0

Home Blog Tag Molecular partners

Molecular Partners

Dec 21, 2018

Tetra, Shionogi sign deal; Amgen remunerates; Gilead’s fibrotic disease deal

Tetra, Shionogi sign USD 40 Million deal for Alzheimer’s disease and fragile X syndrome Tetra Discovery Partners is collaborating with Shionogi to progress its PDE4-targeting drug in Alzheimer’s disease and fragile X syndrome. Shionogi will give a USD 5 million upfront payment and USD 35 million in equ...

Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies

Snippets - A Small piece of News or Article

Jul 04, 2025

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

Articles

Jun 10, 2025

ADCs in Lung Cancer Treatment: ENHERTU’s Rise, HER3 & TROP-2 Challenges, and What’s Next in the Pipeline

Articles

May 09, 2025

LEQEMBI: A New Hope for Alzheimer’s Disease Patients

Articles